Clinical Trial Update: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hepatic arterial infusion chemotherapy combined with donafenib and sintilimab for unresectable intrahepatic cholangiocarcinoma has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Donafenib (donafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhongda Hospital | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED